Screener / SEC EDGAR /CIK 0001699031 /10-K filed Mar 12, 2026, compared with Mar 5, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Medical Labs

GRAIL, Inc. GRAL

We are an innovative commercial-stage healthcare company focused on shifting the paradigm in early cancer detection at population scale. 10-K, Item 1

Headquarters
Sunnyvale, CA
CEO
Joshua J. Ofman
Next results
around Jan 11, 2027
Compare with peers Embed

GRAL among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 17.2%, above 69% of 154 peers (their median 10.4%) REVENUE GROWTH 17.2% · above 69% Operating margin: -347.3%, above 4% of 138 peers (their median 10.2%) OPERATING MARGIN -347.3% · above 4% Net margin: -243.8%, above 5% of 153 peers (their median 6.8%) NET MARGIN -243.8% · above 5% FCF margin: -187.3%, above 6% of 144 peers (their median 10.1%) FCF MARGIN -187.3% · above 6%
GRAL Peer median Below the median

What changed

44 new risk paragraphs. 10-K filed Mar 12, 2026 against Mar 5, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

9 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 9 checks found nothing to note

  • Receivables -9.9% ($20.3M to $18.3M) vs revenue +17.2% ($125.6M to $147.2M), -27.1 pts apart
  • Cash from operations −$299.0M vs net income −$408.4M (FY ending Dec 31, 2025)
  • Same auditor in both 10-Ks: Ernst & Young LLP
6 more checks with nothing to note
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

44 paragraphs in Risk Factors that were not in the 10-K filed Mar 5, 2025. Quoted as filed.

All 44 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Mar 5, 2025 10-K, ITEM 1A
    Our NHS-Galleri Trial did not meet its stated primary endpoint, which may adversely affect our business, stock price, and ability to obtain regulatory approvals, coverage and reimbursement, or achieve commercial adoption. In February 2026, we announced topline results from our NHS-Galleri Trial, which enrolled approximately 140,000…
  2. Item 1A · new paragraph · not in the 10-K filed Mar 5, 2025 10-K, ITEM 1A
    For example, in February 2026, we announced topline results from the NHS-Galleri Trial, which did not achieve its primary endpoint of statistically significant combined Stage 3 and 4 cancer reduction. Not meeting the stated primary endpoint may lead healthcare providers, payors, regulators, and the investment community to question the…
  3. Item 1A · new paragraph · not in the 10-K filed Mar 5, 2025 10-K, ITEM 1A
    Our clinical trials to date have been conducted on an earlier version of Galleri. We have in the past improved, and intend in the future to improve, our products to enhance performance, offerings, scalability, and/or cost of sales, including through the launches of new versions. However, we may not be successful in transitioning our…
  4. Item 1A · new paragraph · not in the 10-K filed Mar 5, 2025 10-K, ITEM 1A
    In February 2026, the Nancy Gardner Sewell Medicare MCED Coverage Act became law and created a Medicare coverage benefit category for multi-cancer early detection tests. The law included certain standards, including that CMS would establish coverage through a national coverage determination (“NCD”) process under “reasonable and…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$55.5M$93.1M$125.6M$147.2M
Net income−$5.4B−$1.5B−$2.0B−$408.4M
Operating cash flow−$561.3M−$595.8M−$577.2M−$299.0M
Free cash flow−$584.2M−$608.7M−$582.4M−$299.9M

Revenue, FY2022 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$147.2M ▲ 17.2% in FY2025

FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

2 filings in the last 30 days · SEC EDGAR

All filings

About the company

GRAIL, Inc., Sunnyvale, CA · from the 10-K filed Mar 12, 2026

We are an innovative commercial-stage healthcare company focused on shifting the paradigm in early cancer detection at population scale. We believe screening individuals for many types of cancer with a single test represents a significant opportunity to reduce the global burden of cancer. Our multi-cancer early detection test (“Galleri”) can screen for many types of cancer, accurately predicting the specific organ or tissue type where the cancer signal originated (the “Cancer Signal of Origin”, or “CSO”), with high positive predictive values (“PPV”) and low false positive rates, all from a simple blood draw.

Headquarters
Sunnyvale, CA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 4, 2026
Incorporated in
DE

Email alerts

Sources

The 10-K filed Mar 12, 2026 (open at SEC), compared with the 10-K filed Mar 5, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GRAL/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.